Published in Arch Intern Med on March 08, 1999
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med (2010) 1.53
Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med (2005) 1.48
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol (2013) 1.20
Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis (2011) 1.08
A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med (2010) 1.04
Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost (2008) 0.99
Treatment of deep vein thrombosis: what factors determine appropriate treatment? Can Fam Physician (2005) 0.92
Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf (2014) 0.89
Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis (2013) 0.88
Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist (2012) 0.88
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol (2003) 0.85
Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial Fibrillation. Cardiol Res Pract (2012) 0.84
A simplified clinical prediction score of chronic kidney disease: a cross-sectional-survey study. BMC Nephrol (2011) 0.84
Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res (2010) 0.82
Complication of warfarin therapy presenting as empyema. J Thorac Dis (2011) 0.80
Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. Vasc Health Risk Manag (2013) 0.79
Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage. Korean Circ J (2009) 0.79
Current strategies to minimize the bleeding risk of warfarin. J Blood Med (2013) 0.79
Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit (2011) 0.79
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Acad Emerg Med (2016) 0.79
Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. Medicine (Baltimore) (2015) 0.78
Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. J Stroke Cerebrovasc Dis (2013) 0.77
Oral anticoagulant-associated intracerebral hemorrhage. J Neurol (2011) 0.77
Adding chemoprophylaxis to sequential compression might not reduce risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis (2012) 0.76
The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One (2015) 0.76
Should symptomatic, isolated distal deep vein thrombosis be treated with anticoagulation? Int J Angiol (2009) 0.76
Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice. Medicine (Baltimore) (2015) 0.75
Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland. Clin Epidemiol (2016) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. PLoS One (2016) 0.75
Impact of Comorbidity and Prescription Drugs on Haemorrhage in Cholecystectomy. World J Surg (2017) 0.75
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 4.92
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
Meta-analysis: the final answer, or even more confusion? Lancet (1996) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost (1999) 2.18
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev (2004) 2.16
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg (2011) 2.14
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
Deep-vein thrombosis. Lancet (1999) 1.98
Triage of patients for short term observation after elective coronary angioplasty. Heart (2000) 1.97
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
Compression ultrasonography of the leg veins in patients with clinically suspected pulmonary embolism: is a more extensive assessment of compressibility useful? Thromb Haemost (2000) 1.95
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost (2005) 1.70
Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost (2010) 1.69
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost (2006) 1.69
Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr (2001) 1.68
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg (1996) 1.68
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Thyroid diseases and cerebrovascular disease. Stroke (2005) 1.63
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J (2001) 1.62
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
Reliable rapid blood test for the exclusion of venous thromboembolism in symptomatic outpatients. Thromb Haemost (1996) 1.61
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol (1999) 1.60
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost (1999) 1.60
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost (1997) 1.56
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med (1997) 1.54
Family history and inherited thrombophilia. J Thromb Haemost (2006) 1.52
Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost (2009) 1.52
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Accuracy of single-detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy. J Thromb Haemost (2005) 1.46
Combined use of clinical pretest probability and D-dimer test in cancer patients with clinically suspected deep venous thrombosis. J Thromb Haemost (2006) 1.46
The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost (2001) 1.45
Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost (2007) 1.44
Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev (2005) 1.43
Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial. J Vasc Surg (1999) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Venous thromboembolism--prophylactic and therapeutic practice guideline. S Afr Med J (2009) 1.42
Active implementation of a consensus strategy improves diagnosis and management in suspected pulmonary embolism. QJM (2000) 1.42